as 12-23-2024 9:48am EST
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Founded: | 2009 | Country: | United States |
Employees: | N/A | City: | AUSTIN |
Market Cap: | 854.2K | IPO Year: | 2018 |
Target Price: | $10.00 | AVG Volume (30 days): | 877.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -10.34 | EPS Growth: | N/A |
52 Week Low/High: | $0.28 - $14.40 | Next Earning Date: | 11-13-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
GNPX Breaking Stock News: Dive into GNPX Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
PR Newswire
7 days ago
Pharmaceutical Technology
a month ago
MT Newswires
a month ago
PR Newswire
a month ago
MT Newswires
2 months ago
PR Newswire
2 months ago
PR Newswire
2 months ago
The information presented on this page, "GNPX Genprex Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.